Chief Scientist of the Republic Demetris Skourides paid his first official visit to SOZO Brain Center in Nicosia recently, as part of his ongoing commitment to engage with Cyprus’ research and innovation ecosystem.
The aim, a press release said, was to review the organisation’s research activities, clinical practices, and international collaborations in the field of neuromodulation and AI-enabled medicine.
Skourides was hosted by SOZO CEO Matthew Papadopoulos and brain.space CEO Yair Levy, together with SOZO’s multidisciplinary research team. The visit included presentations on ongoing projects, global partnerships, and a live demonstration of the “Brain Sensei” AI-powered neurotechnology helmet. During the demonstration, the Chief Scientist experienced how real-time neurophysiological data is collected, analysed, and transformed into actionable insights for clinicians, adhering to GDPR and privacy laws.
The SOZO research department, comprising more than 10 neuroscientists and clinicians, shared its work with the Chief Scientist, highlighting contributions to international scientific dialogue. SOZO’s findings have already been presented at global conferences such as the World Congress of Neurology and the International Neuromodulation Society World Congress, with further publications planned in peer-reviewed journals.
The Center also briefed Skourides on its medical training programmes. To date, over 150 doctors from 14 countries have been trained in SOZO’s neuromodulation protocols. More than 60 clinicians have become certified SOZO Fellows, actively applying these therapies in their own practices. Collectively, this network has treated more than 3,500 patients worldwide.
Looking ahead, SOZO Brain Center is advancing three strategic pillars to support global collaboration:
- Clinical Trials Centre (CTC) – aligned with UK and US standards, producing clinical evidence on neuromodulation therapies.
- CME-Accredited e-Learning Platform – enabling continuous training and certification of clinicians worldwide.
- Train-the-Trainer Workshops – expanding the faculty of trainers to scale access internationally.
Through its SOZO Partnerships, the organisation has also established co-branded clinics in Berlin, Vienna, Melbourne, and Athens, integrating its treatment protocols into local medical practice. In parallel, SOZO has also set out its intention to develop agentic AI agents in healthcare.
Following the visit, Skourides said: “Cyprus’ research and innovation ecosystem continues to grow stronger through the work of scientists, clinicians, and entrepreneurs who are advancing solutions with global impact. My visit to SOZO Brain Center offered valuable insights into the pioneering research being conducted in Cyprus, the international collaborations being forged, and the ways in which innovation here contributes to the broader scientific and medical community.”
Skourides added that, “it is exciting to see how artificial intelligence is being used in healthcare here in Cyprus. SOZO’s commitment to developing technologies such as Agentic AI within medical protocols, and the broader investment by Cypriot innovation companies in building strong R&D capabilities, reflect the ambition of Cyprus’ national Research and Development Strategy 2024–2026.”
Matthew Papadopoulos added: “It was a privilege to welcome the Chief Scientist and present to him the progress our team has achieved. At SOZO, we are advancing a first-of-its-kind agentic AI platform with brain.space, creating global standards in neuromodulation, and building an international network of trained physicians who are already transforming patient care. With clinical trials, new co-branded clinics in major cities, and our CME-accredited e-learning platform, we are scaling innovation from Cyprus to the world. I am personally excited to be part of this journey, as we work to redefine how neurological and mental health conditions are understood and treated globally.”
The visit formed part of the Chief Scientist’s broader mission to support applied research, foster commercialisation, and strengthen international partnerships. By engaging with organisations such as SOZO Brain Center, the Chief Scientist highlights Cyprus’s growing role in shaping global innovation while ensuring that research excellence translates into tangible benefits for patients and society.
SOZO Brain Center, based in Cyprus, is a research and clinical organisation focused on neuromodulation therapies and AI-driven medical technologies. Through international collaborations, training programmes, and clinical partnerships, SOZO contributes to advancing neuroscience and improving patient outcomes worldwide. SOZO Brain Center’s growth and international credibility are anchored in its strong intellectual property portfolio. The company holds proprietary rights to the Functional Network-Oriented Neuromodulation (FNON) Protocol, a unique, clinically validated methodology that integrates multiple neuromodulation modalities for chronic, neurological, and mental health conditions. SOZO’s IP further encompasses copyrighted physician manuals, treatment SOPs, patient education materials, AI-driven diagnostic reporting systems, and e-learning modules that are exclusively licensed through the SOZO Fellowship — a global license agreement enabling doctors worldwide to apply these methods in their own practices. In addition, SOZO manages internationally registered trademarks for its brand and aims to develop patentable innovations in neuromodulation device manufacturing by late 2026. This comprehensive IP strategy ensures the protection, scalability, and ethical application of SOZO’s methods while reinforcing Cyprus’s position as a global reference hub for neuromodulation treatments.
